Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 10:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 133 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Axillary surgery Clear all
Completed Phase 4 Interventional

Magseed Magnetic Marker in Locating Axillary Lymph Nodes in Patients With Breast Cancer Undergoing Surgery

NCT03038152
View directory record Official record
Conditions
Breast Carcinoma Metastatic in Lymph Node, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7
Interventions
Axillary Lymph Node Dissection, Localization, Medical Device
Procedure · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Sep 10, 2026, 10:08 PM EDT
Recruiting Phase 3 Interventional

A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer

NCT06144164
View directory record Official record
Conditions
Lymphedema, Lymphedema Arm, Lymphedema of Upper Arm, Breast Cancer, Breast Carcinoma, Female Breast Cancer
Interventions
Immediate Lymphatic Reconstruction, Volumetric arm measurements, Lymphatic massage, Range of motion exercises, Compression garment use
Procedure · Diagnostic Test · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 10, 2026, 10:08 PM EDT
Terminated Not applicable Interventional

Axillary Lymph Node Tattoo Marking Study

NCT04947917
View directory record Official record
Conditions
Breast Cancer, Lymph Node Metastases
Interventions
SpotTM Tattoo Ink
Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Sep 10, 2026, 10:08 PM EDT
Completed Not applicable Interventional

Ultrasound Guided Core Biopsy vs Fine Needle Aspiration for Evaluation of Axillary Lymphadenopathy

NCT01920139
View directory record Official record
Conditions
Focus: Breast Cancer With Axillary Node Metastasis
Interventions
Fine needle aspiration and core biopsy of lymph node, Axillary surgery, Titanium marker
Procedure · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 8, 2013 · Synced Sep 10, 2026, 10:08 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

NCT05629585
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Durvalumab, Capecitabine, Pembrolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
88
States / cities
Gilbert, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 70 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 10, 2026, 10:08 PM EDT
Completed Phase 2 Interventional

Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer

NCT00005800
View directory record Official record
Conditions
Breast Cancer
Interventions
Filgrastim, Docetaxel, Doxorubicin, Surgery
Biological · Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Sep 10, 2026, 10:08 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Quadratus Lumborum Block on Recovery Profile After Ventral Hernia Repair

NCT03794882
View directory record Official record
Conditions
Pain, Postoperative, Opioid Use
Interventions
Quadratus Lumborum Block, Standard Medical Management
Combination Product · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 10, 2026, 10:08 PM EDT
Completed Not applicable Interventional

Selective Image Guided Resection of Pathologically Documented Axillary Lymph Node Metastases

NCT03281720
View directory record Official record
Conditions
Breast Cancer
Interventions
TAD
Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 10, 2026, 10:08 PM EDT
Active, not recruiting Phase 3 Interventional

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

NCT01901094
View directory record Official record
Conditions
Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
Axillary Lymph Node Dissection (ALND), Nodal Radiation Therapy, Axillary Radiation Therapy
Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
2,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2031
U.S. locations
1228
States / cities
Daphne, Alabama • Mobile, Alabama • Anchorage, Alaska + 730 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 10, 2026, 10:08 PM EDT
Recruiting Not applicable Interventional

Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery

NCT07140172
View directory record Official record
Conditions
Breast Cancer
Interventions
Axillary lymph node dissection (ALND), Axillary radiotherapy (ART)
Procedure
Lead sponsor
University Hospital, Basel, Switzerland
Other
Eligibility
18 Years and older
Enrollment
1,060 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
4
States / cities
Bethesda, Maryland • Durham, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 10, 2026, 10:08 PM EDT
Recruiting Not applicable Interventional

Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma

NCT03941756
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma, Melanoma
Interventions
Indocyanine Green, Lymphangiography, Lymphovenous Bypass
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 10, 2026, 10:08 PM EDT
Completed Phase 2 Interventional

Axillary Reverse Mapping

NCT01381315
View directory record Official record
Conditions
Breast Cancer
Interventions
Injection of isotope, Axillary lymph node dissection
Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Sep 10, 2026, 10:08 PM EDT
Completed No phase listed Observational

Temperature Measurement in Post-Anesthesia Care Units

NCT00614588
View directory record Official record
Conditions
Surgery, Postoperative, Laparoscopic Surgery, General Anesthesia
Interventions
Body temperature thermometers
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Sep 10, 2026, 10:08 PM EDT
Terminated Phase 3 Interventional

S9623, Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

NCT00002772
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, carboplatin, carmustine, cisplatin, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, thiotepa, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Sep 10, 2026, 10:08 PM EDT
Completed No phase listed Observational

Specimen X-Rays of Removed Axillary Lymph Nodes to Guide Pathological Sampling

NCT01156454
View directory record Official record
Conditions
Breast Cancer
Interventions
X-ray
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Sep 10, 2026, 10:08 PM EDT
Active, not recruiting Not applicable Interventional

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

NCT01872975
View directory record Official record
Conditions
Stage IB Breast Cancer, Stage II Breast Cancer
Interventions
regional nodal XRT, chestwall XRT, WBI
Radiation
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
1,636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
489
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 356 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Sep 10, 2026, 10:08 PM EDT
Active, not recruiting Phase 2 Interventional

Axillary Reverse Mapping

NCT00572481
View directory record Official record
Conditions
Cancer of the Breast
Interventions
Axillary Reverse Mapping
Procedure
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Sep 10, 2026, 10:08 PM EDT
Completed Not applicable Interventional

Sentinel Lymph Node Biopsy and Primary Tumor Gene Expression Profiling in Finding Axillary Lymph Node Metastases in Women Who Have Received Neoadjuvant Therapy for Stage II, Stage III, or Stage IV Breast Cancer

NCT00080860
View directory record Official record
Conditions
Breast Cancer
Interventions
microarray analysis, immunohistochemistry staining method, conventional surgery, lymphangiography, radionuclide imaging, sentinel lymph node biopsy, technetium Tc 99m sulfur colloid
Genetic · Other · Procedure + 1 more
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Sep 10, 2026, 10:08 PM EDT
Active, not recruiting Phase 2 Interventional Results available

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

NCT01723774
View directory record Official record
Conditions
Breast Neoplasms
Interventions
PD0332991, Anastrozole, Goserelin, Surgery (standard of care), Tumor biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
4
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 10, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Results available

Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer

NCT00675259
View directory record Official record
Conditions
Breast Cancer
Interventions
bevacizumab, carboplatin, nab-paclitaxel, Surgery, Adjuvant chemotherapy
Drug · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Sep 10, 2026, 10:08 PM EDT
Completed Phase 1 Interventional

Fluorescent Dyes for Lymph Node Mapping

NCT01095913
View directory record Official record
Conditions
Breast Cancer
Interventions
Indocyanine green (ICG)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2015 · Synced Sep 10, 2026, 10:08 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

NCT02623972
View directory record Official record
Conditions
Inflammatory Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions
Eribulin, Adriamycin, Cyclophosphamide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 10, 2026, 10:08 PM EDT
Recruiting No phase listed Observational

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

NCT05059444
View directory record Official record
Conditions
Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma
Interventions
Guardant Reveal
Diagnostic Test
Lead sponsor
Guardant Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
33
States / cities
Birmingham, Alabama • Chandler, Arizona • Hot Springs, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 10, 2026, 10:08 PM EDT
Completed Phase 3 Interventional

Prognostic Study of Sentinel Lymph Node and Bone Marrow Metastases in Women With Stage I or Stage IIA Breast Cancer

NCT00003854
View directory record Official record
Conditions
Breast Cancer
Interventions
immunohistochemistry staining method, lymphangiography, sentinel lymph node biopsy, therapeutic conventional surgery, whole breast irradiation
Other · Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
4,590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
113
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 10, 2026, 10:08 PM EDT